pharma · NEULANDLAB
Neuland Laboratories
Neuland Laboratories: PE below historical average. ROTATIONAL regime.
Price
₹23,568
Price 2026-08-20
5 day
+1.06%
Short-term move
1 month
+24.96%
Medium-term
Regime
ROTATIONAL
68% confidence
Market cap
₹24.2k Cr
neutral sector flow
Market Intelligence Analyst
Understand today's market in about 2 minutes.
“How does today's ROTATIONAL regime affect Neuland Laboratories (NEULANDLAB) in the pharma sector?”
Price chart
₹23,370
+63.85% over period
About Neuland Laboratories
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
At a Glance
RSI pattern warning
RSI oversold bounces for this stock succeeded only 0% of the time (avg -13.2% over 14 days) — not a reliable pattern.
52-week position
Trading at 119.3% of 52-week high
Technicals
RSI 14
77
Trend
uptrend
50 DMA
Above
200 DMA
Above
Key metrics
P/E ratio
66.5
43th pct · 7 quarterly points (limited history)
P/B
12.9
Market cap
₹24.2k Cr
Revenue growth
13640.0% YoY
Promoter
37.8%
52-week range
₹11,500 – ₹19,747
119.3% of high
RSI (14)
77.0
uptrend
vs 50 DMA
Above
DMA ₹19,470.36
Coverage
89/100
HIGH
Quick Take
Neuland Laboratories: PE below historical average. ROTATIONAL regime.
Peer comparison
| Stock | Price | 5D | P/E | ROE | Rev growth | Mcap |
|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹8,570 | +0.8% | 70 | 16.2% | 950% | ₹1.8L Cr |
| CIPLA Cipla | ₹1,438 | -1.4% | 30.2 | 11.7% | -210% | ₹1.2L Cr |
| DRREDDY Dr. Reddy's Laboratories | ₹1,180 | -2.2% | 26.5 | 11.8% | -1160% | ₹1.1L Cr |
| AUROPHARMA Aurobindo Pharma | ₹1,608 | -3.3% | 26.3 | 9.9% | 560% | ₹91.1k Cr |
| ALKEM Alkem Laboratories | ₹5,400 | -0.9% | 29.4 | 17.6% | 1460% | ₹67.8k Cr |
| BIOCON Biocon | ₹412.5 | -1.8% | 145.3 | 1.1% | 230% | ₹66.3k Cr |
| GLENMARK Glenmark Pharmaceuticals | ₹2,332.9 | +0.6% | 47 | 14.1% | 1430% | ₹63.9k Cr |
| GLAND Gland Pharma | ₹2,820 | -5.0% | 40.9 | 10.5% | 2230% | ₹42.1k Cr |
| NEULANDLAB Neuland Laboratories | ₹23,568 | +1.6% | 66.5 | N/A | 13640% | ₹24.2k Cr |
Tensions to watch
Promoter holding at 37.8% — neither distress selling nor aggressive buying
No strong insider signal. Watch for changes in promoter stake as a leading indicator.
Key Watchpoints
Breaks above ₹24746 (+5%)
Trend reversal confirmation
Breaks below ₹22390 (-5%)
Further downside risk
PE reverts to median of 66.5 (7 quarterly points (limited history))
Valuation normalization
Pharma sector entering leadership
Sector rotation signal
